Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/99366
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis
Author: Ahmadian, A.
Brogan, A.
Berman, J.
Sverdlov, A.
Mercier, G.
Mazzini, M.
Govender, P.
Ruberg, F.
Miller, E.
Citation: Journal of Nuclear Cardiology, 2014; 21(5):925-939
Publisher: Springer
Issue Date: 2014
ISSN: 1071-3581
1532-6551
Statement of
Responsibility: 
Azadeh Ahmadian, Ashley Brogan, Jeffrey Berman, Aaron L. Sverdlov, Gustavo Mercier, Michael Mazzini, Praveen Govender, Frederick L. Ruberg, and Edward J. Mille
Abstract: Background: FDG PET/CT with myocardial perfusion imaging is a useful method for evaluating cardiac sarcoidosis (CS), but interpretation is not standardized. We developed a method for quantification of cardiac FDG PET/CT and evaluated its relationship to conventional interpretation, perfusion defects, clinical events, and immunosuppressive treatment. Methods and Results: FDG PET/CT with MPI studies performed for CS (n = 38) were retrospectively compared to negative control studies acquired for oncologic indications (n = 10). Quantitative measures of FDG volume-intensity (Cardiac Metabolic Activity, CMA) was performed using standardized uptake values (SUVs). CMA (477.7 ± 909 vs 0.55 ± 2.1 vs 0.3 ± 0.3 g glucose, P = .02) was significantly greater in visually FDG-positive studies compared to visually negative and oncologic negative studies. Among patients with CS, CMA was greater in studies with an EF < 50% (760.3 ± 1,148 vs 87.4 ± 161 g glucose, P = .03) and preceding an adverse clinical event (1,095 ± 1,253 vs 73 ± 144 g glucose, P = .006). CMA was the only independent predictor of events by multivariate analysis. In patients with repeat examinations (n 5 7), CMA decreased with prednisone treatment in 5 of 6 patients. Conclusions: Quantification of FDG uptake in CS correlates with lower EFs, clinical events, and immunosuppression treatment.
Keywords: Metabolism: PET; PET/CT imaging; fluorodeoxyglucose (FDG)
Rights: Copyright © 2014 American Society of Nuclear Cardiology.
RMID: 0030014528
DOI: 10.1007/s12350-014-9901-9
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.